CRC Research Update — October 07, 2026
Today's colorectal cancer research highlights
her2
A collection of 32 issues
Zanidatamab shows activity in HER2-amplified metastatic colorectal cancer after multiple prior lines
Skip to content
The CRC Digest
▸ TREATMENT
Zanidatamab shows activity in HER2-amplified metastatic colorectal cancer after multiple prior lines
A case report demonstrates zanidatamab-based therapy as a potential option for HER2-positive metastatic disease, particularly in patients with cetuximab resistance driven by ERBB2 amplification. (Frontiers in Pharmacology)
This content is informational
CRC Research Update — October 02, 2026
Today's colorectal cancer research highlights
Pembrolizumab plus HER2-targeted ADC tested in pretreated HER2-positive mCRC
Skip to content
The CRC Digest
▸ TREATMENT
Pembrolizumab plus HER2-targeted ADC tested in pretreated HER2-positive mCRC
A multicenter phase II study evaluated pembrolizumab combined with disitamab vedotin, an anti-HER2 antibody-drug conjugate, in patients with microsatellite stable, HER2-positive metastatic colorectal cancer who had received at least two prior lines of therapy.
CRC Research Update — September 27, 2026
Today's colorectal cancer research highlights
Trastuzumab Rezetecan Extends Progression-Free Survival in HER2-Positive Metastatic Colorectal Cancer
Skip to content
The CRC Digest
◆ TRIAL DATA
Trastuzumab Rezetecan Extends Progression-Free Survival in HER2-Positive Metastatic Colorectal Cancer
The phase III HORIZON-CRC-01 trial showed that the HER2-directed antibody-drug conjugate trastuzumab rezetecan improved median progression-free survival to 5.5 months versus 2.8 months with standard care in patients with chemotherapy-refractory,
CRC Research Update — September 24, 2026
Today's colorectal cancer research highlights
Trastuzumab rezetecan extends progression-free survival in HER2-positive metastatic colorectal cancer
Skip to content
The CRC Digest
◆ TRIAL DATA
Trastuzumab rezetecan extends progression-free survival in HER2-positive metastatic colorectal cancer
The phase III HORIZON-CRC-01 trial showed median progression-free survival of 5.5 months with the antibody-drug conjugate versus 2.8 months with standard care, a 67% reduction in risk of progression or
CRC Research Update — September 06, 2026
Today's colorectal cancer research highlights
Real-world data on HER2-positive metastatic CRC from 14 Japanese centers
Skip to content
The CRC Digest
◇ RESEARCH
Real-world data on HER2-positive metastatic CRC from 14 Japanese centers
A multicenter retrospective study of 45 patients with HER2-positive metastatic colorectal cancer diagnosed between 2010 and 2023 examined outcomes with different first-line targeted agents and assessed safety of trastuzumab plus pertuzumab. (International Journal